About Technology Issues FAQ

Links

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.